Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

1(16.7%)

N/A

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 1(3)

Phase 2(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02354170Phase 2Completed

Short-Term Oral Mifepristone for Central Serous Chorioretinopathy

Role: collaborator

NCT02897583Not ApplicableCompleted

YAG Vitreolysis for Floaters

Role: lead

NCT01724554Phase 1Completed

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

Role: lead

NCT00395551Phase 1Completed

Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Role: lead

NCT00491166Phase 1Unknown

Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser

Role: lead

NCT00347828Phase 4Unknown

Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

Role: lead

All 6 trials loaded